<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864951</url>
  </required_header>
  <id_info>
    <org_study_id>1186/2021</org_study_id>
    <nct_id>NCT04864951</nct_id>
  </id_info>
  <brief_title>HPV Prevalence in Transpersons - a Prospective Study</brief_title>
  <official_title>HPV Prevalence in Transpersons - a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sophie Pils</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, Human Papilloma Virus (HPV) prevalence will be determined once in the urine of&#xD;
      200 trans people. In addition, subjects will be asked to complete a questionnaire about their&#xD;
      sexual orientation, which is adapted from the largest published study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All transpeople who visit the outpatient clinic are asked to participate in the study. After&#xD;
      being informed and signing the Informed Consent Form, the subjects are asked to give&#xD;
      first-void urine and fill out the survey. The urine samples are sent pseudonymously to the&#xD;
      University of Ljubljana for analysis. The subjects will be informed about their results&#xD;
      within 3 weeks.If the result is positive, the subjects will be offered voluntary further care&#xD;
      in our HPV outpatient clinic. However, this will take place outside the study. The data&#xD;
      collected there can be used for further analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HPV prevalence in transpeople</measure>
    <time_frame>one year</time_frame>
    <description>HPV prevalence in transpeople</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Papillomavirus Infection</condition>
  <condition>Transsexualism</condition>
  <arm_group>
    <arm_group_label>Transpeople</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1x urine sampling for HPV analysis&#xD;
1x survey</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Colli-Pee urine collection device</intervention_name>
    <description>first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplexâ„¢ II HPV HR Detection from Seegene.</description>
    <arm_group_label>Transpeople</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey</intervention_name>
    <description>Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking</description>
    <arm_group_label>Transpeople</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Transpeople&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Sufficient knowledge of German&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18 years&#xD;
&#xD;
          -  Insufficient knowledge of German&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>all study participants classify themselves as transmen, transwomen, genderqueer, non-binary or other gender identity</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elmar Joura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie Pils, MD</last_name>
    <phone>004314040029150</phone>
    <email>sophie.pils@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Pils, MD</last_name>
      <phone>004314040029150</phone>
      <email>sophie.pils@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Elmar Joura, MD</last_name>
      <phone>004314040029150</phone>
      <email>elmar.joura@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institute of Microbiology and Immunology Faculty of Medicine</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Poljak, MD, PhD</last_name>
      <phone>+386 1 543 7453</phone>
      <email>Mario.Poljak@mf.uni-lj.si</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Reisner SL, Deutsch MB, Peitzmeier SM, White Hughto JM, Cavanaugh TP, Pardee DJ, McLean SA, Panther LA, Gelman M, Mimiaga MJ, Potter JE. Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients. PLoS One. 2018 Mar 14;13(3):e0190172. doi: 10.1371/journal.pone.0190172. eCollection 2018.</citation>
    <PMID>29538411</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>October 2, 2021</last_update_submitted>
  <last_update_submitted_qc>October 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Sophie Pils</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

